RGIN (Regenicin) Interest Expense: $-0.04 Mil (TTM As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenicin Interest Expense?

Regenicin RGIN -99.00% Interest Expense is $-0.04 Mil as of Mar. 2023.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Regenicin's interest expense for the three months ended in Mar. 2023 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Regenicin's Operating Income for the three months ended in Mar. 2023 was $ -0.33 Mil. Regenicin's Interest Expense for the three months ended in Mar. 2023 was $ -0.01 Mil. Regenicin did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Regenicin  (OTCPK:RGIN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Regenicin's Interest Expense for the three months ended in Mar. 2023 was $-0.01 Mil. Its Operating Income for the three months ended in Mar. 2023 was $-0.33 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2023 was $0.00 Mil.

Regenicin's Interest Coverage for the quarter that ended in Mar. 2023 is calculated as

Regenicin did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Regenicin Interest Expense Historical Data

* Premium members only.

The historical data trend for Regenicin's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenicin Interest Expense Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.02 -0.05 -0.04 -0.04

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Regenicin Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.04 Mil mean?
Regenicin (RGIN) has a Interest Expense of $-0.04 Mil as of Mar. 2023. Interest Expense is the amount a company pays on its long-term debt. View historical data on Regenicin and its competitors.
Is Regenicin's Interest Expense too high?
Regenicin's current Interest Expense is $-0.04 Mil.
How does Regenicin's Interest Expense compare to NOVNQ and TMBRQ?
Regenicin's Interest Expense of $-0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Regenicin and its competitors. Regenicin's current Interest Expense is $-0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenicin stock overvalued right now?
Regenicin (RGIN) has a current Interest Expense of $-0.04 Mil. The current Interest Expense is $-0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Regenicin (RGIN), the current Interest Expense is $-0.04 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenicin Business Description

Address 10530 Discovery Drive, Las Vegas, NV, USA, 89135
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.